Providing more reliable prognostic insights and enhancing treatment planning and patient outcomes is the driving force behind a recent research by ImpriMed in feline oncology.
Published in Veterinary Sciences, “Prognostic Utility of the Flow Cytometry and Clonality Analysis Results for Feline Lymphomas,” investigates the utility of flow cytometry and clonality analysis via PCR for antigen receptor rearrangement (PARR) in characterizing feline lymphoma and predicting prognosis.
Study findings highlight the effectiveness of the precision medicine startup company’s flow cytometry-based approach in distinguishing between small, medium, and large cell sizes correlating with patient survival rates. The system reportedly achieved an 82 to 90 percent concordance with the gold standard of cytology.
The study used fine needle aspirates and/or blood samples from 438 feline patients and analyzed them. Flow cytometry parameters, particularly forward scatter thresholds, were optimized for cell size categorization. Key findings include:
- The novel cell-sizing method showed 82 percent concordance with cytological sizing in a training set and 90 percent concordance in an independent test set.
- Expanded research with more patients showed significant survival differences: cats with small-cell lymphomas survived the longest (median 312 days), followed by medium-cell (median 189 days), and large-cell with a median survival time of 81 days.
- Lymphoma subtypes defined by flow cytometry and PARR demonstrated significant survival differences, emphasizing the system’s potential prognostic utility.
“We are thrilled to share our breakthrough findings with the veterinary community,” says Sungwon Lim, ImpriMed’s CEO and co-founder in a statement released by the company. “Our innovative cell-sizing method is a significant advancement in the fight against feline lymphomas, equipping veterinarians nationwide with enhanced tools for accurate diagnosis and effective treatment of this challenging disease.”
For more information, visit ImpriMed’s website.